The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–204 of 204
Zhu, Y., Qi, M., Lao, L., Wang, W., Hua, L., & Bai, G. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2013.0419 · Cited by 8
Wang‐Gillam, A., Li, C., Bodoky, G., Dean, A. P., Shan, Y.-S., Jameson, G., Macarulla, T. M., Lee, K.-H., Cunningham, D., Blanc, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.417 · Cited by 8
Is type 2 diabetes a risk factor for pancreatic cancer?
Pezzilli, R., Casadei, R., & Morselli‐Labate, A. M. (2009) · PubMed · Cited by 7
Wang‐Gillam, A., Li, C., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T. M., Lee, K.-H., Cunningham, D., Blanc, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4126 · Cited by 1
Cited by
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 865
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 512
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., Sripadam, R., Mukherjee, S., Soonawalla, Z., Wadsley, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00348-x · Cited by 337
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
Dbouk, M., Katona, B. W., Brand, R. E., Chak, A., Syngal, S., Farrell, J. J., Kastrinos, F., Stoffel, E. M., Blackford, A. L., Rustgi, A. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00298 · Cited by 247
“Since 2018,National Comprehensive CancerNetwork guidelines have recommended individuals with PDAC and their first-degree relatives be offered susceptibility gene testing.(21,22) Among the 26 PDACs, 19 were detected during surveillance, 57.”
Background
Metadata
- Authors
- Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., Dillhoff, M., Donahue, T. R., Dotan, E., Ferrone, C. R., Fountzilas, C., Hardacre, J., Hawkins, W. G., Klute, K., Ko, A. H., Kunstman, J. W., LoConte, N., Lowy, A. M., Moravek, C., Nakakura, E. K., Narang, A. K., Obando, J., Polanco, P. M., Reddy, S., Reyngold, M., Scaife, C., Shen, J., Vollmer, C., Wolff, R. A., Wolpin, B. M., Lynn, B., & George, G. V.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-04
- Volume
- 19
- Issue
- 4
- Pages
- 439-457
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3153075376
- Cited by
- 1,304
- References
- 204
- FWCI
- 69.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.